The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

The GARDP Foundation and Debiopharm have entered a collaboration and license agreement to pursue the development of a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

Kisumu and nearby towns carry the heaviest burden of drug-resistant gonorrhoea in Kenya, according to a new genetic study of ...

New options for testing and treating some of the most common sexually transmitted diseases are becoming available ...

Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria ...

Last year, the US authorities approved the first at-home test that can detect three common infections in women — gonorrhea, ...

46 new molecular entities cleared the agency’s hurdles last year, 4 fewer than in 2024 ...

A team of scientists from the Institut Pasteur has used the database of the National Reference Center for Meningococci to trace the evolution of invasive meningococcal disease cases in France between ...

A dangerous fungus is spreading across hospitals and nursing homes nationwide, including in New York and New Jersey. Candida ...

A deadly, drug-resistant fungus has infected more than 7,000 people across 27 U.S. states, including Mississippi, in 2025, ...

A promising drug combination could help people with leukemia who don't respond to traditional treatments, according to new research. A team at Oregon Health and Science University made the discovery ...

A new study involving the Medical University of Vienna shows how the multi-resistant fungus Candida auris utilizes carbon dioxide (CO₂) to survive on the skin and become resistant to antifungal ...